You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 2, 2024

CLINICAL TRIALS PROFILE FOR PENNSAID


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for PENNSAID

Trial ID Title Status Sponsor Phase Start Date Summary
NCT01119898 ↗ Exploratory Study of PENNSAID Gel to Treat Symptoms of Knee Osteoarthritis Completed Mallinckrodt Phase 2 2010-08-02 Osteoarthritis (OA) is the most common form of arthritis. It can cause pain, swelling, and reduced motion in the joints. That can reduce quality of life. OA can occur in any joint, but usually affects the hands, knees, hips or spine. The purpose of this study is to find out if doctors might be able to use 2% PENNSAID gel to treat OA in the knee.
NCT01202799 ↗ Pharmacokinetics, Bioavailability and Safety of PENNSAID® Gel Completed Mallinckrodt Phase 1 2010-09-01 It is anticipated that PENNSAID Gel will minimize systemic exposure versus oral diclofenac administered twice a day (BID). In addition, PENNSAID Gel should result in greater subject convenience and compliance with a comparable bioavailability, safety and tolerability profile to that of the approved PENNSAID solution administered four times a day (QID).
NCT01350622 ↗ Efficacy of PENNSAID® for Pain Management in the Emergency Department Withdrawn Medtronic - MITG N/A 2011-12-01 The primary objective of this study is to compare the pain relieving effect and speed of onset of PENNSAID to that of standard oral diclofenac under double blind conditions using a growth curve approach to pain measurement. The investigators will test the hypothesis that PENNSAID will provide more rapid pain relief than oral diclofenac during the ED visit. The secondary goal of the proposed work is to discover and model the onset and course of pain relief during the emergency department (ED) visit.
NCT01350622 ↗ Efficacy of PENNSAID® for Pain Management in the Emergency Department Withdrawn University of Utah N/A 2011-12-01 The primary objective of this study is to compare the pain relieving effect and speed of onset of PENNSAID to that of standard oral diclofenac under double blind conditions using a growth curve approach to pain measurement. The investigators will test the hypothesis that PENNSAID will provide more rapid pain relief than oral diclofenac during the ED visit. The secondary goal of the proposed work is to discover and model the onset and course of pain relief during the emergency department (ED) visit.
NCT01350622 ↗ Efficacy of PENNSAID® for Pain Management in the Emergency Department Withdrawn Virgil Davis N/A 2011-12-01 The primary objective of this study is to compare the pain relieving effect and speed of onset of PENNSAID to that of standard oral diclofenac under double blind conditions using a growth curve approach to pain measurement. The investigators will test the hypothesis that PENNSAID will provide more rapid pain relief than oral diclofenac during the ED visit. The secondary goal of the proposed work is to discover and model the onset and course of pain relief during the emergency department (ED) visit.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for PENNSAID

Condition Name

Condition Name for PENNSAID
Intervention Trials
Osteoarthritis of the Knee 2
Pain 2
Postherpetic Neuralgia 1
Reflex Sympathetic Dystrophy 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for PENNSAID
Intervention Trials
Osteoarthritis 3
Osteoarthritis, Knee 2
Emergencies 1
Hemostatic Disorders 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for PENNSAID

Trials by Country

Trials by Country for PENNSAID
Location Trials
United States 17
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for PENNSAID
Location Trials
Florida 2
South Carolina 1
Ohio 1
North Carolina 1
Missouri 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for PENNSAID

Clinical Trial Phase

Clinical Trial Phase for PENNSAID
Clinical Trial Phase Trials
Phase 3 1
Phase 2 1
Phase 1 1
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for PENNSAID
Clinical Trial Phase Trials
Completed 4
Withdrawn 1
Approved for marketing 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for PENNSAID

Sponsor Name

Sponsor Name for PENNSAID
Sponsor Trials
Mallinckrodt 3
Medtronic - MITG 2
Nathan Wei, MD, FACP, FACR: 1
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for PENNSAID
Sponsor Trials
Industry 6
Other 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.